hero image

A statement from Biogen on LEQEMBI™ pricing

January 6, 2023 Company Statements

Biogen would like to commend our collaboration partner, Eisai, on today's U.S. Food and Drug Administration approval of LEQEMBITM via the Accelerated Approval pathway. Additional details can be found in a news release announcing the approval. An additional news release from Eisai on patient safety is available on Eisai’s website.

A separate news release from Eisai on LEQEMBI pricing is also available via their website.  Eisai is solely responsible for setting LEQEMBI’s price.

thumb
June 1, 2023
Biogen Announces Webcast of Annual Meeting of Stockholders

Cambridge, Mass. – June 1, 2023 – Biogen Inc. (Nasdaq: BIIB) announced today that the webcast of the Company's 2023 Annual Meeting of Stockholders will be held on Wednesday, June 14, 2023, at 9:00 a.m. Eastern Time.  A live audio webcast of the meeting will be available on the Investor Relations

thumb
May 23, 2023
Biogen to Participate in the Jefferies Healthcare Conference

Cambridge, MA, - -  Biogen Inc.   (Nasdaq: BIIB) announced today that Michael McDonnell, Chief Financial Officer, and Priya Singhal, M.D., M.P.H., Head of Development, will participate in the Jefferies Healthcare Conference. The webcast will be live on Wednesday, June 7, 2023, at 11:30 a.m.